Sodium Ioxaglate | Ioxaglic Acid | CAS#67992-58-9 | CAS#59017-64-0 | Contrast Agent

MedKoo Cat#: 328712 | Name: Sodium Ioxaglate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sodium Ioxaglate (also known as Ioxaglic Acid, MP-302, and P-286) is a drug used as a contrast agent

Chemical Structure

Sodium Ioxaglate

CAS#67992-58-9 (Sodium)

Theoretical Analysis

MedKoo Cat#: 328712

Name: Sodium Ioxaglate

CAS#: 67992-58-9 (Sodium)

Chemical Formula: C25H21I6N4NaO8

Exact Mass: 1289.5525

Molecular Weight: 1289.88

Elemental Analysis: C, 23.28; H, 1.64; I, 59.03; N, 4.34; Na, 1.78; O, 9.92

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

67992-58-9 (Sodium) 59017-64-0 (free acid)

Synonym

Sodium Ioxaglate; Ioxaglic acid; MP-302; P-286; MP 302; P 286; MP302; P286

IUPAC/Chemical Name

sodium 3-((2-hydroxyethyl)carbamoyl)-2,4,6-triiodo-5-(2-(2,4,6-triiodo-3-(N-methylacetamido)-5-propionylbenzamido)acetamido)benzoate

InChi Key

XGFANPFGNXSPRX-UHFFFAOYSA-M

InChi Code

InChI=1S/C25H22I6N4O8.Na/c1-4-9(38)11-15(26)13(20(31)22(19(11)30)35(3)8(2)37)24(41)33-7-10(39)34-21-17(28)12(23(40)32-5-6-36)16(27)14(18(21)29)25(42)43;/h36H,4-7H2,1-3H3,(H,32,40)(H,33,41)(H,34,39)(H,42,43);/q;+1/p-1

SMILES Code

OCCNC(C1=C(I)C(C([O-])=O)=C(I)C(NC(CNC(C2=C(I)C(C(CC)=O)=C(I)C(N(C(C)=O)C)=C2I)=O)=O)=C1I)=O.[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 67992-58-9 (Sodium Ioxaglate) 59017-64-0 (Ioxaglic Acid)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,289.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Conrozier T, Patarin J, Mathieu P, Rinaudo M. Steroids, lidocain and ioxaglic acid modify the viscosity of hyaluronic acid: in vitro study and clinical implications. Springerplus. 2016 Feb 24;5:170. doi: 10.1186/s40064-016-1762-z. eCollection 2016. PubMed PMID: 27026867; PubMed Central PMCID: PMC4766165. 2: Vishwanath S, Baroody FM, Chaaban MR, deTineo M, Lasser KH, Lasser EC, Naclerio RM. Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen. J Allergy Clin Immunol. 2011 Jul;128(1):219-21. doi: 10.1016/j.jaci.2011.02.024. Epub 2011 Mar 17. PubMed PMID: 21414657. 3: Obermann WR, Bloem JL, Hermans J. Knee arthrography: comparison of iotrolan and ioxaglate sodium meglumine. Radiology. 1989 Oct;173(1):197-201. PubMed PMID: 2781008. 4: Obermann WR, Kieft GJ. Knee arthrography: a comparison of iohexol, ioxaglate sodium meglumine, and metrizoate. Radiology. 1987 Mar;162(3):729-33. PubMed PMID: 3544035. 5: Trägårdh B, Lynch PR. Effects of ioxaglic acid on cardiac functions during coronary arteriography in canines. Acta Radiol Diagn (Stockh). 1983;24(1):43-7. PubMed PMID: 6869056. 6: Kanny G, Marie B, Hoen B, Trechot P, Moneret-Vautrin DA. Delayed adverse reaction to sodium ioxaglic acid-meglumine. Eur J Dermatol. 2001 Mar-Apr;11(2):134-7. PubMed PMID: 11275812. 7: Labarthe B, Idee JM, Burnett R, Corot C. In vivo comparative antithrombotic effects of ioxaglate and iohexol and interaction with the platelet antiaggregant clopidogrel. Invest Radiol. 2003 Jan;38(1):34-43. PubMed PMID: 12496519. 8: Lakin BA, Ellis DJ, Shelofsky JS, Freedman JD, Grinstaff MW, Snyder BD. Contrast-enhanced CT facilitates rapid, non-destructive assessment of cartilage and bone properties of the human metacarpal. Osteoarthritis Cartilage. 2015 Dec;23(12):2158-66. doi: 10.1016/j.joca.2015.05.033. Epub 2015 Jun 9. PubMed PMID: 26067518; PubMed Central PMCID: PMC4841831. 9: Török I, Vadon G, Engloner L. [Ioxaglic acid, a contrast medium with low osmolarity in clinical use]. Rontgenblatter. 1983 Jun;36(6):191-3. German. PubMed PMID: 6879067. 10: Morin JP, Boutelet I, Toutain H, Fillastre JP. [Comparative pharmacokinetics and renal accumulation of the iodized contrast media: ioxitalamic acid, ioxaglic acid and iohexol in the rabbit]. Pathol Biol (Paris). 1987 Nov;35(9):1215-20. French. PubMed PMID: 3320896. 11: Neiss AC, Barth P, Chastin I, Erdmann E. Comparison of sodium-meglumine ioxaglate and iopromide in coronary angiography. Ann Radiol (Paris). 1989;32(1):49-53. PubMed PMID: 2662884. 12: Brennan RE, Rapoport S, Weinberg I, Pollack HM, Curtis JA. CT-determined canine kidney and urine iodine concentration following intravenous administration of sodium diatrizoate, metrizamide, iopamidol, and sodium ioxaglate. Invest Radiol. 1982 Jan-Feb;17(1):95-100. PubMed PMID: 7076442. 13: Smith DC, Lois JF, Gomes AS, Maloney MD, Yahiku PY. Pulmonary arteriography: comparison of cough stimulation effects of diatrizoate and ioxaglate. Radiology. 1987 Mar;162(3):617-8. PubMed PMID: 3544028. 14: Li LP, Thacker J, Lu J, Franklin T, Zhou Y, Papadopoulou MV, Solomon R, Prasad PV. Efficacy of preventive interventions for iodinated contrast-induced acute kidney injury evaluated by intrarenal oxygenation as an early marker. Invest Radiol. 2014 Oct;49(10):647-52. doi: 10.1097/RLI.0000000000000065. PubMed PMID: 24872003; PubMed Central PMCID: PMC4470575. 15: Morris TW, Dukovic D, Pagani E. Cardiac hemodynamic effects of iodixanol, iopamidol, and ioxaglate following left coronary injections in anesthetized dogs. Acad Radiol. 1995 Jan;2(1):33-7. PubMed PMID: 9419521.